Outcomes research in chronic viral hepatitis C: effects of interferon therapy.
Bonkovsky HL, Woolley JM.
Can J Gastroenterol. 2000 Jul-Aug;14 Suppl B:21B-29B. doi: 10.1155/2000/127317.
PMID:10938501
Procollagen-III peptide and chronic viral C hepatitis.
Jeffers LJ, Coelho-Little ME, Cheinquer H, Vargas C, Civantos F, Alvarez L, Reddy KR, Parker T, de Medina M, Li X, et al.
Am J Gastroenterol. 1995 Sep;90(9):1437-40.
PMID:7661165
Treatment of chronic type B hepatitis with multiple ten-day courses of adenine arabinoside monophosphate.
Hoofnagle JH, Davis GL, Hanson RG, Pappas SC, Peters MG, Avigan MI, Waggoner JG, Howard R, Jones EA, Straus SE.
J Med Virol. 1985 Feb;15(2):121-8. doi: 10.1002/jmv.1890150204.
PMID:2579192
Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV coinfection on the severity of the disease in a Brazilian population.
Pereira LM, Spinelli V, Ximenes RA, Cavalcanti MS, Melo R, Jucá N, Mizokami M, McFarlane IG.
J Med Virol. 2002 May;67(1):27-32. doi: 10.1002/jmv.2188.
PMID:11920814
A high seroprevalence of human herpesvirus type 8 already present in patients with chronic hepatitis before the development of cirrhosis.
Tsai JP, Tseng KC, Lin MN, Su CC.
Pathology. 2019 Jan;51(1):86-90. doi: 10.1016/j.pathol.2018.10.005. Epub 2018 Nov 27.
PMID:30497802
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
Thromb Res. 2009;123(3):537-42. doi: 10.1016/j.thromres.2008.06.013. Epub 2008 Aug 8.